Breaking News

CureVac to Receive €252M to Support COVID-19 Vax Development

The German Federal Ministry of Education and Research grant is also expected to be used for the rapid expansion of vaccine production.

By: Contract Pharma

Contract Pharma Staff

CureVac N.V., a biopharmaceutical company developing a new class of medicines based on messenger ribonucleic acid (mRNA), has received notification from the German Federal Ministry of Education and Research (BMBF) that CureVac is expected receive up to €252 million to support the development of its COVID-19 vaccine candidate. In July 2020, CureVac applied for a grant to accelerate the research and development of urgently needed vaccines against SARS-CoV-2. In addition to the further developm...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters